454 related articles for article (PubMed ID: 23726147)
1. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains.
Evren E; Azap OK; Çolakoğlu Ş; Arslan H
Diagn Microbiol Infect Dis; 2013 Jul; 76(3):335-8. PubMed ID: 23726147
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
[TBL] [Abstract][Full Text] [Related]
3. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
[TBL] [Abstract][Full Text] [Related]
4. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases.
Santimaleeworagun W; Wongpoowarak P; Chayakul P; Pattharachayakul S; Tansakul P; Garey KW
Southeast Asian J Trop Med Public Health; 2011 Jul; 42(4):890-900. PubMed ID: 22299471
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.
Tängdén T; Hickman RA; Forsberg P; Lagerbäck P; Giske CG; Cars O
Antimicrob Agents Chemother; 2014; 58(3):1757-62. PubMed ID: 24395223
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.
Endimiani A; Patel G; Hujer KM; Swaminathan M; Perez F; Rice LB; Jacobs MR; Bonomo RA
Antimicrob Agents Chemother; 2010 Jan; 54(1):526-9. PubMed ID: 19901089
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates.
Gaibani P; Lombardo D; Lewis RE; Mercuri M; Bonora S; Landini MP; Ambretti S
J Antimicrob Chemother; 2014 Jul; 69(7):1856-65. PubMed ID: 24648503
[TBL] [Abstract][Full Text] [Related]
9. Three Dimensional Checkerboard Synergy Analysis of Colistin, Meropenem, Tigecycline against Multidrug-Resistant Clinical Klebsiella pneumonia Isolates.
Stein C; Makarewicz O; Bohnert JA; Pfeifer Y; Kesselmeier M; Hagel S; Pletz MW
PLoS One; 2015; 10(6):e0126479. PubMed ID: 26067824
[TBL] [Abstract][Full Text] [Related]
10. Study of
Zhang W; Guo Y; Yang Y; Dong D; Zheng Y; Zhu D; Hu F
Microb Drug Resist; 2020 Mar; 26(3):204-210. PubMed ID: 31553260
[No Abstract] [Full Text] [Related]
11. Time-kill synergy tests of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
Yim H; Woo H; Song W; Park MJ; Kim HS; Lee KM; Hur J; Park MS
Ann Clin Lab Sci; 2011; 41(1):39-43. PubMed ID: 21325253
[TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
Oliva A; Scorzolini L; Cipolla A; Mascellino MT; Cancelli F; Castaldi D; D'Abramo A; D'Agostino C; Russo G; Ciardi MR; Mastroianni CM; Vullo V
J Antimicrob Chemother; 2017 Jul; 72(7):1981-1984. PubMed ID: 28369424
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of polymyxin B plus imipenem, meropenem, or tigecycline against KPC-2-producing Enterobacteriaceae with high MICs for these antimicrobials.
Barth N; Ribeiro VB; Zavascki AP
Antimicrob Agents Chemother; 2015; 59(6):3596-7. PubMed ID: 25801560
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Cha R
Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
[TBL] [Abstract][Full Text] [Related]
15. In vitro synergistic activity of fosfomycin in combination with meropenem, amikacin and colistin against OXA-48 and/or NDM-producing
Erturk Sengel B; Altinkanat Gelmez G; Soyletir G; Korten V
J Chemother; 2020 Sep; 32(5):237-243. PubMed ID: 32228228
[No Abstract] [Full Text] [Related]
16. In vitro antibacterial activity of fosfomycin combined with other antimicrobials against KPC-producing Klebsiella pneumoniae.
Yu W; Shen P; Bao Z; Zhou K; Zheng B; Ji J; Guo L; Huang C; Xiao Y
Int J Antimicrob Agents; 2017 Aug; 50(2):237-241. PubMed ID: 28648647
[TBL] [Abstract][Full Text] [Related]
17. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development.
Souli M; Galani I; Boukovalas S; Gourgoulis MG; Chryssouli Z; Kanellakopoulou K; Panagea T; Giamarellou H
Antimicrob Agents Chemother; 2011 May; 55(5):2395-7. PubMed ID: 21321144
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of antibiotic synergy for NDM-1-producing Enterobacteriaceae.
Berçot B; Poirel L; Dortet L; Nordmann P
J Antimicrob Chemother; 2011 Oct; 66(10):2295-7. PubMed ID: 21807739
[TBL] [Abstract][Full Text] [Related]
19. Emergence in Japan of an imipenem-susceptible, meropenem-resistant Klebsiella pneumoniae carrying blaIMP-6.
Shigemoto N; Kuwahara R; Kayama S; Shimizu W; Onodera M; Yokozaki M; Hisatsune J; Kato F; Ohge H; Sugai M
Diagn Microbiol Infect Dis; 2012 Jan; 72(1):109-12. PubMed ID: 22078906
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.
Galani I; Souli M; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Antoniadou A;
Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1143-1150. PubMed ID: 30825054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
